Introduction of the herpes simplex virus type 1 thymidine ganciclovir, were endowed with a pronounced bystander kinase gene into tumor cells, followed by the administration killer effect. Lobucavir (Cyclobut-G), a ganciclovir anaof the antiherpes nucleoside analogue ganciclovir has logue, displayed a two-to three-fold more pronounced been demonstrated to be effective in eliminating solid bystander killer effect than ganciclovir, eliminating, at a tumors in animals. The success of this combination treatconcentration of 10 M, 75% and 90% of a cell population ment largely depends on the bystander effect, ie the killing that contained 5% and 10% tk gene-transfected cells, of nontransfected tumor cells by activated drug carried respectively. These findings were corroborated by autoover from the nearby herpes thymidine kinase (tk) generadiographic analysis that showed that 2′-3 H-BVDU metabtransfected cells. We evaluated the in vitro bystander effect olites formed in the herpes tk gene-transfected tumor cells of several antiherpes purine and pyrimidine nucleoside were much less efficiently incorporated in the DNA of analogues, using a colorimetric assay. All pyrimidine bystander cells than 8-3 H-GCV. This indicates that, under nucleoside analogues, including (E)-5-(2-bromovinyl)-2′-the same experimental conditions, BVDU metabolites deoxyuridine (BVDU), showed low, if any, bystander killing are less prone to pass the gap junctions than GCV effect. In contrast, purine nucleoside analogues, such as metabolites.